紫杉醇单药及联合顺铂治疗老年晚期非小细胞肺癌的临床观察

Clinical observation of effect of TAX alone Versus TAX plus Cisplatin for Treatment of Elderly Patients with Non-small Cell Lung Cancer

目的观察紫杉醇(TAX)单药与TAX+顺铂(DDP)治疗老年晚期NSCLC的疗效和不良反应。方法经病理学或细胞学证实的58例晚期非小细胞肺癌随机分为两组,A组:应用TAX单药化疗,B组:TAX+DDP联合化疗,21天为一个周期,均治疗2周期以上。观察经两方案治疗后的缓解率(RR)、临床获益率(CR+PR+SD)、1年生存率和不良反应。结果A组及B组的有效率分别为31.0%和37.9%(P=0.22);临床获益率(CR+PR+SD)分别为72.4%和79.3%(P=0.73);1年生存率分别为43.3%和46.4%(P=0.52);单药组的消化道毒性、骨髓毒性及肾脏损伤均显著低于联合组(P<0.05)。结论紫杉醇单药或联合顺铂均是治疗老年晚期NSCLC的较好方案,二者疗效相似,单药紫杉醇毒副反应更少见,较易为老年患者接受。

Objective To explore the effects and toxicities of TAX alone and TAX plus Cisplatin in treatment of elderly NSCLC patients. Methods A total of 58 patients with advanced elderly NSCLC patients diagnosed by pathology were randomly divided into two groups. Group A and Group B. In Group A Only TAX was given. In Group B TAX and DDPwere given with 21 days as a cycle. All patients received at least two-cycle treatment. To evaluate Response rates （RR） and clinical Response rates（ CR ＋ PR ＋ SD） 1 -year survival rate and toxicoty. Results The response rate of patients were 31.0% in A group and 37.9% in B group （ P = 0. 22）. The clinical Response rates （ C R ＋ PR ＋ SD） of patients were 72. 4% and 79. 3 % （P = 0. 73 ） ; The 1-year survival rate were 43.3 % and 46. 4% （P = 0. 52）. The rates of nausea/vomiting, myelo-supression and kidney damage in A group were lower than those in B group （P 〈 0. 05 ）. Conclusion TAX alone and TAX plus Cisplatin are both effective for elderly advanced NSCLC. But the toxicities are lower in TAX alone group which is favorable for the elderly.